LPCN: Lipocine Inc Company Profile & Statistics

About

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Info & Links

CEO

Mahesh V. Patel

Headquarters

675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, UT 84108, UNITED STATES

Auditor

Tanner LLC

Share holders

Employees

Lipocine Inc Statistics

Valuation Measures

Market Capitalization²

25.79M

Enterprise Value

22.04M

Enterprise Value/EBITDA(ttm)

-3.65

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

1.40

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

75.00%

Operating Margin(ttm)

Profit Margin(ttm)

-1108.93%

Return on Equity(ttm)

-19.17%

Return on Invested Capital(ttm)

-22.60%

Return on Assets(ttm)

-17.60%

Income Statement

Revenue(ttm)

7.92M

Revenue Per Share(ttm)

1.48

Gross Profit(ttm)

7.92M

EBITDA(ttm)³

-6.04M

Net Income Available to Common(ttm)

-4.06M

Diluted EPS(ttm)

-0.76

Share Statistics

Beta (5Y Monthly)

1.24

52-Week Change

76.56%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

5.35M

Dividend Yield

0.00%

Float⁴

5.02M

% Held by Insiders

6.12%

% Held by Institutions

9.11%

Balance Sheet

Total Cash(mrq)

19.82M

Total Cash Per Share(mrq)

3.71

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.97%

Quick Ratio(mrq)

12.97%

Book Value Per Share(mrq)

3.57

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.55

Free Cash Flow(ytd)

-3.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LPCN

Lipocine Inc

Lipocine Inc Profile